Related News
Xarelto.com、 Thrombosis Adviser、抗血栓療法トライアルデータベース、3つの サイトより、AF治療や抗血栓療法に関する論文や記事、トライアルを紹介いたします。 新しい話題について、随時更新してまいります。

2015
2014
2013
Gussoni G, Di Pasquale G, Vescovo G, Gulizia M, Mathieu G, Scherillo M, Panuccio D, Lucci D, Nozzoli C, Fabbri G, Colombo F, Riva L, Baldo CI, Maggioni AP, Mazzone A; ATA-AF Steering Committee and Investigators
Decision making for oral anticoagulants in atrial fibrillation: The ATA-AF study
Eur J Intern Med. 2013 Jun;24(4):324-32.
Brandes A, Overgaard M, Plauborg L, Dehlendorff C, Lyck F, Peulicke J, Poulsen SV, Husted S
Guideline Adherence of Antithrombotic Treatment Initiated by General Practitioners in Patients With Nonvalvular Atrial Fibrillation: A Danish Survey
Clin Cardiol. 2013 May 13. [Epub ahead of print]
Whiteley WN, Adams HP Jr, Bath PM, Berge E, Sandset PM, Dennis M, Murray GD, Wong KS, Sandercock PA
Targeted use of heparin, heparinoids, or low-molecular-weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-analysis of randomised controlled trials
Lancet Neurol. 2013 May 1. [Epub ahead of print]
Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P
EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary
Eur Heart J. 2013 Apr 26. [Epub ahead of print]
Del Conde I, Halperin JL.
Ineligibility for anticoagulation in patients with atrial fibrillation.
Am J Med. 2013 Feb;126(2):105-11.
Hung CY, Lin CH, Loh el-W, Ting CT, Wu TJ.
CHADS(2) Score, Statin Therapy, and Risks of Atrial Fibrillation.
Am J Med. 2013 Feb;126(2):133-140.e1. doi: 10.1016/j.amjmed.2012.06.027.
Roldán V, Marín F, Fernández H, Manzano-Fernandez S, Gallego P, Valdés M, Vicente V, Lip GY.
Renal Impairment in a "Real-Life" Cohort of Anticoagulated Patients With Atrial Fibrillation (Implications for Thromboembolism and Bleeding).
Am J Cardiol. 2013 Jan 18. [Epub ahead of print]
2012

Crijns HJ, Bash LD, Chazelle F, Le Heuzey JY, Lewalter T, Lip GY, Maggioni AP, Martín A, Ponikowski P, Rosenqvist M, Sanders P, Scanavacca M, Bernhardt AA, Unniachan S, Phatak HM, Gitt AK.
RHYTHM-AF: design of an international registry on cardioversion of atrial fibrillation and characteristics of participating centers.
BMC Cardiovasc Disord 2012 Oct 2;12(1):85. [Epub ahead of print]

Donadini MP, Ageno W, Douketis JD.
Management of bleeding in patients receiving conventional or new anticoagulants: a practical and case-based approach.
Drugs 2012 Oct 22;72(15):1965-1975

Song TJ, Kim J, Lee HS, Nam CM, Nam HS, Heo JH, Kim YD.
The frequency of cerebral microbleeds increases with CHADS(2) scores in stroke patients with non-valvular atrial fibrillation.
Eur J Neurol 2012 Oct 11. doi: 10.1111/ene.12003. [Epub ahead of print]
Giralt-Steinhauer E, Cuadrado-Godia E, Ois A, Jiménez-Conde J, Rodríguez-Campello A, Soriano C, Roquer J.
Comparison between CHADS2 and CHA2DS2-VASc score in a stroke cohort with atrial fibrillation.
Eur J Neurol 2012 Jul 27. [Epub ahead of print]
Lahaye SA, Gibbens SL, Ball DG, Day AG, Olesen JB, Skanes AC.
A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation.
Eur Heart J 2012 Jul 2. [Epub ahead of print]
Palm F, Kleemann T, Dos Santos M, Urbanek C, Buggle F, Safer A, Hennerici MG, Becher H, Zahn R, Grau AJ.
Stroke due to atrial fibrillation in a population-based stroke registry (Ludwigshafen Stroke Study) CHADS2 , CHA2 DS2 -VASc score, underuse of oral anticoagulation, and implications for preventive measures.
Eur J Neurol 2012 Jul 12. [Epub ahead of print]
Ruiz-Nodar JM, Marín F, Roldán V, Valencia J, Manzano-Fernández S, Caballero L, Hurtado JA, Sogorb F, Valdés M, Lip GY.
Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score?
Circ Cardiovasc Interv 2012 Jul 10. [Epub ahead of print]
Dobromirski M, Cohen AT.
How I manage venous thromboembolism risk in hospitalized medical patients.
Blood 2012 Aug 23;120(8):1562-1569
Pinto DJ, Qiao JX, Knabb RM.
The emergence of factor Xa inhibitors for the treatment of cardiovascular diseases: a patent review.
Expert Opin Ther Pat 2012 Jun 3. [Epub ahead of print]
Roldán V, Marín F, Fernández H, Manzano-Fernandez S, Gallego P, Valdés M, Vicente V, Lip GY.
Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a 'real world' anticoagulated atrial fibrillation population.
Chest 2012 Jun 21. [Epub ahead of print]
Geeganage CM, Sprigg N, Bath MW, Bath PM.
Balance of Symptomatic Pulmonary Embolism and Symptomatic Intracerebral Hemorrhage with Low-dose Anticoagulation in Recent Ischemic Stroke: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
J Stroke Cerebrovasc Dis  2012 Apr 17.[Epub ahead of print]
Kearon C.
A conceptual framework for two phases of anticoagulant treatment of venous thromboembolism.
J Thromb Haemost 2012 Apr;10(4):507-511.
Mason PK, Lake DE, Dimarco JP, Ferguson JD, Mangrum JM, Bilchick K, Moorman LP, Moorman JR.
Impact of the CHA2DS2-VASc Score on Anticoagulation Recommendations for Atrial Fibrillation.
Am J Med 2012 Apr 11. [Epub ahead of print]
Omran H, Bauersachs R, Rübenacker S, Goss F, Hammerstingl C.
The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the national multicentre BNK Online bRiDging REgistRy (BORDER).
Thromb Haemost 2012 Apr 26;108(1). [Epub ahead of print]
Lahtela H, Rubboli A, Schlitt A, Karjalainen PP, Niemelä M, Vikman S, Puurunen M, Weber M, Valencia J, Biancari F, Lip GY, Airaksinen KE; for the AFCAS (Management of patients with Atrial Fibrillation undergoing Coronary Artery Stenting) study group.
Heparin Bridging vs. Uninterrupted Oral Anticoagulation in Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting.
Circ J 2012 Mar 9. [Epub ahead of print]
Lip GY, Brechin CM, Lane DA.
The Global Burden of Atrial Fibrillation and Stroke: A Systematic Review of the Epidemiology of Atrial Fibrillation in Regions outside North America and Europe.
Chest 2012 Mar 29. [Epub ahead of print]
Neumann I, Rada G, Claro JC, Carrasco-Labra A, Thorlund K, Akl EA, Bates SM, Guyatt GH.
Oral Direct Factor Xa Inhibitors Versus Low-Molecular-Weight Heparin to Prevent Venous Thromboembolism in Patients Undergoing Total Hip or Knee Replacement: A Systematic Review and Meta-analysis.
Ann Intern Med 2012 Mar 16. [Epub ahead of print]
Nieto JA, Espada NG, Merino RG, González TC.
Dabigatran, Rivaroxaban and Apixaban versus Enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: Pool-analysis of phase III randomized clinical trials.
Thromb Res 2012 Mar 14. [Epub ahead of print]
Matute MC, Masjuan J, Egido JA, Fuentes B, Simal P, Díaz-Otero F, Reig G, Díez-Tejedor E, Gil-Nuñez A, Vivancos J, Alonso de Leciñana M.
Safety and outcomes following thrombolytic treatment in stroke patients who had received prior treatment with anticoagulants.
Cerebrovasc Dis 22012;33(3):231-239. Epub 2012 Jan 19.
2011
Alves C, Batel-Marques F, Macedo AF.
Apixaban and rivaroxaban safety after hip and knee arthroplasty: a meta-analysis
J Cardiovasc Pharmacol Ther   2011 Dec 1. [Epub ahead of print]
Banerjee A, Lane DA, Torp-Pedersen C, Lip GY.
Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study
Thromb Haemost  2011 Dec 21;107(3). [Epub ahead of print]
Gao Q, Fu X, Wei JW, Chen X, Huang Y, Wang J, Anderson CS, Wong KS.
China QUEST Study Investigators. Use of oral anticoagulation among stroke patients with atrial fibrillation in China: the ChinaQUEST (Quality evaluation of stroke care and treatment) registry study
Int J Stroke 2011 Dec 14.
Garwood CL, Hwang JM, Moser LR.
Striking a balance between the risks and benefits of anticoagulation bridge therapy in patients with atrial fibrillation: clinical updates and remaining controversies
Pharmacotherapy 2011 Dec;31(12):1208-1220.
Samama MM, Contant G, Spiro TE, Perzborn E, Guinet C, Gourmelin Y, Le Flem L, Rohde G, Martinoli JL for the Rivaroxaban Anti-Factor Xa Chromogenic Assay Field Trial Laboratories.
Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls
Thromb Haemost 2011 Dec 21;107(2). [Epub ahead of print]
Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM; ATLAS ACS 2-TIMI 51 Investigators.
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
N Engl J Med 2011 Nov 13. [Epub ahead of print]
Walkey AJ, Wiener RS, Ghobrial JM, Curtis LH, Benjamin EJ.
Incident stroke and mortality associated with new-onset atrial fibrillation in patients hospitalized with severe sepsis
JAMA 2011 Nov 13. [Epub ahead of print]
Krauel K, Hackbarth C, Fürll B, Greinacher A.
Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies
Blood 2011 Nov 2. [Epub ahead of print]
Oldgren J, Alings M, Darius H, Diener HC, Eikelboom J, Ezekowitz MD, Kamensky G, Reilly PA, Yang S, Yusuf S, Wallentin L, Connolly SJ; on behalf of the RE-LY Investigators.
Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial
Ann Intern Med 2011 Nov 15;155(10):660-667.
Almeida GD, Noblat LD, Passos LC, do Nascimento HF.
Quality of Life analysis of patients in chronic use of oral anticoagulant: an observational study.
Health Qual Life Outcomes.  2011 Oct 25;9(1):91. [Epub ahead of print]
Fraenkel L, Street RL Jr, Fried TR.
Development of a tool to improve the quality of decision making in atrial fibrillation
BMC Med Inform Decis Mak. 2011 Oct 6;11(1):59. [Epub ahead of print]
Fleming TR, Emerson SS.
Evaluating rivaroxaban for nonvalvular atrial fibrillation - regulatory considerations
N Engl J Med.  2011 Oct 5. [Epub ahead of print]
Gerotziafas GT, Baccouche H, Sassi M, Galea V, Chaari M, Hatmi M, Samama MM, Elalamy I.
Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban.
Thromb Res.  2011 Oct 12. [Epub ahead of print]
Giralt-Steinhauer E, Cuadrado-Godia E, Ois A, Jiménez-Conde J, Rodríguez-Campello A, Planellas L, Jimena-García S, Rubio MA, Roquer-González J.
CHA2DS2-VASc score and prognosis in ischemic strokes with atrial fibrillation
J Neurol. 2011 Oct 8. [Epub ahead of print]
Matsumoto M, Okazaki S, Sakaguchi M, Ohara N, Furukado S, Nagano K, Kuwagata Y, Shimazu T, Yoshimine T, Kitagawa K.
Preadmission therapeutic anticoagulation reduces cerebral infarct volume in patients with nonvalvular atrial fibrillation.
Eur Neurol. 2011 Oct 21;66(5):277-282. [Epub ahead of print]
Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F
Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention.
Clin Pharmaco. 2011 Oct 1;50(10):675-86
Andersen LV, Mortensen LS, Lip GY, Lindholt JS, Faergeman O, Henneberg EW, Frost L.
Atrial fibrillation and upper limb thromboembolectomy: a national cohort study
J Thromb Haemost. 2011 Sep;9(9):1738-43
Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M
Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects
Circulation 2011 Sep 6 [Epub ahead of print]
Gattellari M, Goumas C, Aitken R, Worthington JM
Outcomes for Patients with Ischaemic Stroke and Atrial Fibrillation: The PRISM Study (A Program of Research Informing Stroke Management)
Cerebrovasc Dis 2011 Sep 15;32(4):370-382 [Epub ahead of print]
Hong HJ, Kim YD, Cha MJ, Kim J, Lee DH, Lee HS, Nam CM, Nam HS, Heo JH
Early neurological outcomes according to CHADS2 score in stroke patients with non-valvular atrial fibrillation
Eur J Neurol 2011 Sep 14 [Epub ahead of print]
Tichelaar V, de Jong H, Nijland H, Kluin-Nelemans H, Meijer K, Mulder A
Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays.
Thromb Haemost 2011 Sep 8;106(5) [Epub ahead of print]
Welles CC, Whooley MA, Na B, Ganz P, Schiller NB, Turakhia MP.
The CHADS2 score predicts ischemic stroke in the absence of atrial fibrillation among subjects with coronary heart disease: Data from the Heart and Soul Study.
Am Heart J. 2011 Sep;162(3):555-61. Epub 2011 Aug 9.
Asmis LM, Alberio L, Angelillo-Scherrer A, Korte W, Mendez A, Reber G, Seifert B, Stricker H, Tsakiris DA, Wuillemin WA.
Rivaroxaban: quantification by anti-FXa assay and influence on coagulation tests a study in 9 Swiss laboratories
Thromb Res. 2011 Aug 11. [Epub ahead of print]
Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, Paolini JF, Hankey GJ, Mahaffey KW, Patel MR, Singer DE, Califf RM.
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.
Eur Heart J. 2011 Aug 28. [Epub ahead of print]
Goto S, Ikeda Y, Shimada K, Uchiyama S, Origasa H, Kobayashi H; The J-TRACE Investigators.
One-Year Cardiovascular Event Rates in Japanese Outpatients With Myocardial Infarction, Stroke, and Atrial Fibrillation.
Circ J. 2011 Aug 20. [Epub ahead of print]
Harenberg J, Krämer R, Giese C, Marx S, Weiss C, Wehling M.
Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability.
J Thromb Thrombolysis.   2011 Aug 3. [Epub ahead of print]
Moore KT, Plotnikov AN, Thyssen A, Vaccaro N, Ariyawansa J, Burton PB.
Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban.
J Cardiovasc Pharmacol. 2011 Aug 4. [Epub ahead of print]
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; the ROCKET AF Investigators.
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
N Engl J Med.  2011 Aug 10. [Epub ahead of print]
Rodríguez-Mañero M, Cordero A, Bertomeu-González V, Moreno-Arribas J, Bertomeu-Martínez V, Mazón P, Fácila L, Cosín J, Lekuona I, Galve E, González-Juanatey JR
Impact of New Criteria for Anticoagulant Treatment in Atrial Fibrillation
Rev Esp Cardiol 2011 Aug;64(8):649-653. Epub 2011 Jun 8
Bernier MC, Desjardins K, Filiatrault J, Sauriol MA, Martineau J, Gilbert E, Caron S, Lalonde L
Implementation and evaluation of a pharmacy-led thromboprophylaxis campaign in a community hospital
J Thromb Thrombolysis 2011 Jul 17. [Epub ahead of print]
Chen WT, Michael White C, Phung OJ, Kluger J, Ashaye A, Sobieraj D, Makanji S, Tongbram V, Baker WL, Coleman CI
Are the risk factors listed in warfarin prescribing information associated with anticoagulation-related bleeding? A systematic literature review
Int J Clin Pract 2011 Jul;65(7):749-63. doi:10.1111/j.1742-1241.2011.02694.x.
Hannon N, Callaly E, Moore A, Ní Chróinín D, Sheehan O, Marnane M, Merwick A, Kyne L, Duggan J, McCormack PM, Dolan E, Crispino-O'Connell G, Harris D, Horgan G, Williams D, Kelly PJ
Improved Late survival and disability after stroke with therapeutic anticoagulation for atrial fibrillation: A population study
Stroke  2011 Jul 21. [Epub ahead of print]
Hobbs FD, Leach I
Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability.
QJM  2011 Aug 3. [Epub ahead of print]
Lim SH, Calkins H, Sinha SK
Update on the Management of Atrial Fibrillation: Anticoagulation and Medical Therapy
Curr Cardiol Rep 2011 Jul 9. [Epub ahead of print]
Ogilvie IM, Welner SA, Cowell W, Lip GY
Ischaemic stroke and bleeding rates in 'real-world' atrial fibrillation patients
Thromb Haemost 2011 Jul 4;106(1):34-44. Epub 2011 May 26
Partida RA, Giugliano RP
Edoxaban: pharmacological principles, preclinical and early-phase clinical testing
Future Cardiol  2011 Jul;7(4):459-70
Boriani G, Botto GL, Padeletti L, Santini M, Capucci A, Gulizia M, Ricci R, Biffi M, De Santo T, Corbucci G, Lip GY; for the Italian AT-500 Registry Investigators
Improving Stroke Risk Stratification Using the CHADS2 and CHA2DS2-VASc Risk Scores in Patients With Paroxysmal Atrial Fibrillation by Continuous Arrhythmia Burden Monitoring
Stroke 2011 Jun;42(6):1768-1770
Chen WT, White CM, Phung OJ, Kluger J, Ashaye AO, Sobieraj DM, Makanji S, Tongbram V, Baker WL, Coleman CI
Association Between CHADS2 Risk Factors and Anticoagulation-Related Bleeding: A Systematic Literature Review
Mayo Clin Proc  2011 Jun;86(6):509-21.
Hobbs FD, Roalfe AK, Lip GY, Fletcher K, Fitzmaurice DA, Mant J; on behalf of the Birmingham Atrial Fibrillation in the Aged (BAFTA) investigators and Midland Research Practices Consortium (MidReC) network
Performance of stroke risk scores in older people with atrial fibrillation not taking warfarin: comparative cohort study from BAFTA trial
BMJ 2011 Jun 23;342:d3653. doi: 10.1136/bmj.d3653.
Mani H, Hesse C, Stratmann G, Lindhoff-Last E
Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time.
Thromb Haemost  2011 Jun 9;106(1). [Epub ahead of print]
Ogawa S, Koretsune Y, Yasaka M, Aizawa Y, Atarashi H, Inoue H, Kamakura S, Kumagai K, Mitamura H, Okumura K, Sugi K, Yamashita T
Antithrombotic Therapy in Atrial Fibrillation
Circ J  2011 Jun 9. [Epub ahead of print]
Olesen JB, Fauchier L, Lane DA, Taillandier S, Lip GY
Risk factors for stroke and thromboembolism in relation to age amongst patients with atrial fibrillation: The Loire Valley Atrial Fibrillation Project.
Chest 2011 Jun 16. [Epub ahead of print]
Wasmer K, Eckardt L
Management of atrial fibrillation around the world: a comparison of current ACCF/AHA/HRS, CCS, and ESC guidelines
Europace 2011 Jun 28. [Epub ahead of print]
Atarashi H, Inoue H, Okumura K, Yamashita T, Kumagai N, Origasa H; The J-RHYTHM Registry Investigators
Present Status of Anticoagulation Treatment in Japanese Patients With Atrial Fibrillation
Circ J  2011 May 25;75(6):1328-1333
Conen D, Chae CU, Glynn RJ, Tedrow UB, Everett BM, Buring JE, Albert CM
Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation.
JAMA 2011 May 25;305(20):2080-7. PubMed PMID: 21610240; PubMed Central PMCID: PMC3105776.
Gattellari M, Leung DY, Ukoumunne OC, Zwar N, Grimshaw J, Worthington JM
Study protocol: the DESPATCH study: Delivering stroke prevention for patients with atrial fibrillation - a cluster randomised controlled trial in primary healthcare
Implement Sci  2011 May 20;6(1):48. [Epub ahead of print]
Ha SI, Choi DH, Ki YJ, Yang JS, Park G, Chung JW, Koh YY, Chang KS, Hong SP
Stroke prediction using mean platelet volume in patients with atrial fibrillation.
Platelets 2011 May 23. [Epub ahead of print]
Hong KS, Yegiaian S, Lee M, Lee J, Saver JL
Declining stroke and vascular event recurrence rates in secondary prevention trials over the past 50 years and consequences for current trial design.
Circulation 2011 May 17;123(19):2111-9
Olesen JB, Lip GY, Hansen PR, Lindhardsen J, Ahlehoff O, Andersson C, Weeke P, Hansen ML, Gislason GH, Torp-Pedersen C
Bleeding risk in 'real world' patients with atrial fibrillation: Comparison of two established bleeding prediction schemes in a nationwide cohort
J Thromb Haemost 2011 May 27. doi: 10.1111/j.1538-7836.2011.04378.x. [Epub ahead of print]
Sato S, Yazawa Y, Itabashi R, Tsukita K, Fujiwara S, Furui E
Pre-admission CHADS2 score is related to severity and outcome of stroke.
J Neurol Sci  2011 May 11. [Epub ahead of print]
Burghaus R, Coboeken K, Gaub T, Kuepfer L, Sensse A, Siegmund HU, Weiss W, Mueck W, Lippert J
Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation
PLoS One  2011 Apr 22;6(4):e17626
Cleland JG, Coletta AP, Buga L, Antony R, Pellicori P, Freemantle N, Clark AL
Clinical trials update from the American Heart Association Meeting 2010:EMPHASIS-HF, RAFT, TIM-HF, Tele-HF, ASCEND-HF, ROCKET-AF, and PROTECT.
Eur J Heart Fail 2011; Apr;13(4):460-5.
Gnoth MJ, Buetehorn U, Muenster U, Schwarz T, Sandmann S
In Vitro and In Vivo P-glycoprotein Transport Characteristics of Rivaroxaban.
J Pharmacol Exp Ther  2011 Apr 22. [Epub ahead of print]
Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Loehr LR, Soliman EZ, Maclehose R, Konety S, Alonso A
Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study.
Circulation  2011 Apr 12;123(14):1501-8
Nutescu E, Chuatrisorn I, Hellenbart E
Drug and dietary interactions of warfarin and novel oral anticoagulants: an update
J Thromb Thrombolysis 2011; Apr;31(3):326-43.
Poli D, Testa S, Antonucci E, Grifoni E, Paoletti O, Lip GY
Bleeding and stroke risk in a 'real world' prospective primary prevention cohort of atrial fibrillation patients.
Chest 2011 Apr 21. [Epub ahead of print]
Santangeli P, Di Biase L, Sanchez JE, Horton R, Natale A
Atrial Fibrillation Ablation without Interruption of Anticoagulation.
Cardiol Res Pract 2011 Apr 26;2011:837841